SCAFURI, LUCA
 Distribuzione geografica
Continente #
NA - Nord America 305
AS - Asia 137
EU - Europa 133
AF - Africa 7
SA - Sud America 1
Totale 583
Nazione #
US - Stati Uniti d'America 302
IT - Italia 71
SG - Singapore 61
HK - Hong Kong 38
NL - Olanda 28
CN - Cina 21
VN - Vietnam 8
CI - Costa d'Avorio 7
IN - India 6
DE - Germania 5
FI - Finlandia 5
GB - Regno Unito 5
CZ - Repubblica Ceca 4
DK - Danimarca 4
CA - Canada 3
RU - Federazione Russa 3
IR - Iran 2
SE - Svezia 2
UA - Ucraina 2
BE - Belgio 1
EC - Ecuador 1
FR - Francia 1
IE - Irlanda 1
RS - Serbia 1
TH - Thailandia 1
Totale 583
Città #
Chandler 55
Singapore 53
Hong Kong 38
Santa Clara 31
Amsterdam 28
Ashburn 19
Naples 19
Lawrence 12
Millbury 12
Des Moines 10
Napoli 9
Beijing 8
Dong Ket 8
Boston 7
Wilmington 6
Fairfield 5
Helsinki 5
Brno 4
Redwood City 4
Rome 4
Milan 3
Pune 3
Seattle 3
Ardabil 2
Dalmine 2
Houston 2
Kochi 2
Locate di Triulzi 2
Pescara 2
Rovereto 2
Salerno 2
Shenzhen 2
Toronto 2
Zhengzhou 2
Afragola 1
Augusta 1
Brussels 1
Changzhou 1
Chicago 1
Dearborn 1
Dublin 1
Ercolano 1
Frankfurt am Main 1
Gunzenhausen 1
Jiaxing 1
Kronberg 1
Macerata Campania 1
Mugnano Di Napoli 1
Munich 1
New York 1
Novi Sad 1
Nuremberg 1
Quito 1
Shanghai 1
Shenyang 1
Washington 1
Xuzhou 1
Totale 391
Nome #
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial 61
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis 53
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis 50
The use of chest ultrasonography in suspected cases of COVID-19 in the emergency department 50
Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor 48
The influence of prednisone on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer 47
Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide 45
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis 40
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy 37
Perspective: Cancer Patient Management Challenges During the COVID-19 Pandemic 33
Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review 30
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings 30
COVID-19 and prostate cancer: A complex scenario with multiple facets 29
Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone 19
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis 16
Instant messaging in cancer care 14
Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and Beyond 10
Study on the Impact of Hormone Therapy for Prostate Cancer on the Quality of Life and the Psycho-Relational Sphere of Patients: ProQoL 1
Totale 613
Categoria #
all - tutte 3.380
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.380


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202016 0 0 0 0 0 0 0 4 1 1 10 0
2020/202149 1 1 0 3 7 10 2 1 7 1 3 13
2021/202295 4 2 5 0 1 2 1 1 0 9 41 29
2022/2023146 12 8 9 2 19 16 0 23 25 28 4 0
2023/2024103 3 22 12 7 7 9 0 15 2 0 15 11
2024/2025196 38 20 1 12 35 45 45 0 0 0 0 0
Totale 613